Takeda and Alloy Therapeutics partner to make off-the-shelf CAR-T therapies
The companies have teamed up to develop Takeda’s proprietary induced pluripotent stem cell (iPSC) derived CAR-T cell platforms.
Cytiva-Cell & Gene Therapy WP 2
Intellia’s gene editing therapy shows early potential in rare heart condition
bit.bio defends European patent for ‘novel’ opti-ox technology
Purespring secures $105m to start Phase I/II trial of IgAN gene therapy
Editas trades part of Vertex CRISPR therapy licencing rights deal for $57m
GC Therapeutics secures $65m to launch into off-the-shelf iPSC therapy space
ESMO 2024: BMS cuts ties as Immatics regains full rights to bispecific
ProKidney drops Phase III CKD study to focus on US market and save up to $175m
